Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Mallinckrodt
Merck
Express Scripts
Boehringer Ingelheim

Last Updated: September 30, 2022

Investigational Drug Information for PTI-428


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for PTI-428?

PTI-428 is an investigational drug.

There have been 28 clinical trials for PTI-428. The most recent clinical trial was a Phase 3 trial, which was initiated on August 5th 2020.

The most common disease conditions in clinical trials are Alzheimer Disease, Cystic Fibrosis, and Fibrosis. The leading clinical trial sponsors are Pain Therapeutics, Proteostasis Therapeutics, Inc., and Cassava Sciences, Inc.

There are two US patents protecting this investigational drug and twenty-three international patents.

Recent Clinical Trials for PTI-428
TitleSponsorPhase
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's DiseaseCassava Sciences, Inc.Phase 2
Simufilam 100 mg for Mild-to-Moderate Alzheimer's DiseasePremier Research International LLCPhase 3
Simufilam 100 mg for Mild-to-Moderate Alzheimer's DiseaseCassava Sciences, Inc.Phase 3

See all PTI-428 clinical trials

Clinical Trial Summary for PTI-428

Top disease conditions for PTI-428
Top clinical trial sponsors for PTI-428

See all PTI-428 clinical trials

US Patents for PTI-428

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PTI-428 See Plans and Pricing Compounds, compositions, and methods for increasing CFTR activity Proteostasis Therapeutics, Inc. (Boston, MA) See Plans and Pricing
PTI-428 See Plans and Pricing Compounds, compositions, and methods of increasing CFTR activity Proteostasis Therapeutics, Inc. (Boston, MA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PTI-428

Drugname Country Document Number Estimated Expiration Related US Patent
PTI-428 Argentina AR103163 2034-12-23 See Plans and Pricing
PTI-428 Australia AU2015371294 2034-12-23 See Plans and Pricing
PTI-428 Australia AU2020256305 2034-12-23 See Plans and Pricing
PTI-428 Brazil BR112017013710 2034-12-23 See Plans and Pricing
PTI-428 Canada CA2971858 2034-12-23 See Plans and Pricing
PTI-428 China CN107207487 2034-12-23 See Plans and Pricing
PTI-428 European Patent Office EP3237411 2034-12-23 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Mallinckrodt
Merck
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.